Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Ludwig Fischer von Weikersthal | Researchclopedia

Back to researchers

Ludwig Fischer von Weikersthal

Gesundheitsdienst ORCID

291

Works

9,483

Citations

41

h-index

87

i10-index

Research Topics

Colorectal Cancer Treatments and Studies Lung Cancer Treatments and Mutations Gastric Cancer Management and Outcomes

Affiliations

Universität Hamburg2005–2005

Heidelberg University2015–2015

University Hospital Heidelberg2015–2015

Medizinische Hochschule Hannover2009–2009

Gesundheitsdienst2015–2025

Top Works

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

Salah‐Eddin Al‐Batran,Nils Homann,et al.

20192,487 citations

Cancer Treatment and Pharmacology

Cancer Genomics and Diagnostics

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

Volker Heinemann,Ludwig Fischer von Weikersthal,et al.

20141,721 citations

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial

Sebastian Stintzing,Dominik Paul Modest,et al.

2016411 citations

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group

Dominik Paul Modest,Ingrid Ricard,et al.

2016342 citations

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial

Sebastian Stintzing,Pratyaksha Wirapati,et al.

2019192 citations

Phase III Study of Second-Line Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Weekly Compared With 3-Weekly Docetaxel

Wolfgang Schuette,S. Nagel,et al.

2005181 citations

FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial

Volker Heinemann,Ludwig Fischer von Weikersthal,et al.

2020180 citations

SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer

Christian Eichelberg,Walter L. Vervenne,et al.

2015142 citations

Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study

Sebastian Stintzing,Lisa Miller‐Phillips,et al.

2017139 citations